Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Employing a superior BACE1 cleavage sequence to probe cellular APP processing.

Alfredo G Tomasselli1, Isam Qahwash, Thomas L Emmons

  • 1Department of Protein Sciences, Pharmacia Corporation, 301 Henrietta Street, Kalamazoo, MI 49007, USA.

Journal of Neurochemistry
|February 27, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prodromal changes in cortical neuron physiology before amyloid pathology in a mild model of Alzheimer's disease.

Scientific reports·2026
Same author

Corrigendum to "Accumulation of neutral lipids in dystrophic neurites surrounding amyloid plaques in Alzheimer's disease" [2024 Apr;1870(4):167086.].

Biochimica et biophysica acta. Molecular basis of disease·2026
Same author

BACE1 Expression Is Required for Proper Synaptic Vesicle Dynamics in the Hippocampus.

Journal of neurochemistry·2025
Same author

Tubular ER dysfunction in neurodegenerative diseases.

Neurobiology of disease·2025
Same author

Amyotrophic lateral sclerosis and frontotemporal dementia mutation reduces endothelial TDP-43 and causes blood-brain barrier defects.

Science advances·2025
Same author

Correction: Full length RTN3 regulates turnover of tubular endoplasmic reticulum via selective autophagy.

eLife·2025

Researchers identified optimal substrates for beta-secretase 1 (BACE1), an enzyme linked to Alzheimer's disease. These substrates enable precise measurement of BACE1 activity and aid in developing potential therapeutic inhibitors.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Enzymology

Background:

  • Beta-secretase (BACE1) is implicated in Alzheimer's disease pathogenesis due to its role in generating amyloid-beta plaques.
  • Understanding BACE1 substrate specificity is crucial for developing targeted therapeutics.

Purpose of the Study:

  • To characterize the substrate specificity of BACE1.
  • To identify and develop optimal BACE1 substrates for cellular assays and inhibitor design.

Main Methods:

  • Investigated BACE1 cleavage of natural substrates (APP, APPSw), oxidized insulin B chain, and ubiquitin.
  • Synthesized and tested modified APP-derived peptides, including decapeptide and expanded forms with an optimized ISY--EV motif.
  • Developed cellular assays using APP mutants (APPISYEV) to measure BACE1 activity.

Related Experiment Videos

Main Results:

  • A modified APP decapeptide with an ISY--EV sequence at the cleavage site was cleaved 7x faster than APPSw.
  • An expanded APP peptide with this motif showed a further 7x increase in cleavage rate, enabling picomolar BACE1 assays.
  • The APPISYEV mutant served as a superior cellular substrate, highly specific for BACE1 over BACE2.
  • Insertion of the ISY--EV motif at beta or beta' sites directed APP processing.

Conclusions:

  • Optimal BACE1 substrates, particularly APPISYEV, have been identified.
  • These substrates facilitate elucidation of BACE1's cellular enzymatic actions.
  • The findings support the development of BACE1 inhibitors for potential Alzheimer's disease therapy.